Investigating the Effect of Dipyridamole on Hypophosphatemia Treatment in Kidney Transplant Recipients

Ghorban-sabagh, Mahin and Nazemiyan, Fatemeh and Zeraati, Abbas-Ali and Maleki-Abardeh, Mousa and Javidi-Dasht-Bayaz, Reza (2017) Investigating the Effect of Dipyridamole on Hypophosphatemia Treatment in Kidney Transplant Recipients. medical journal of mashhad university of medical sciences, 60 (1). pp. 392-398.

MJMS_Volume 60_Issue 1_Pages 392-398.pdf

Download (1MB) | Preview
Official URL:


Introduction:Hypophosphatemia can be seen in renal transplant recipients. Hyperparathyroidism, glucocorticoid treatment, and impairment of renal tubular phosphate reabsorption are the most common causes of hypophosphatemia in these patients. It is well-known that dipyridamole enhances renal tubular phosphate reabsorption in some clinical conditions. We did not find any information about the effect of dipyridamole in renal transplant recipients (RTRs) with hypophosphatemia. For this reason, we decided to give dipyridamole 28 RTRs with hypophosphatemia. Subjects & methods:A total of 28RTRs whose serum phosphate and creatinine levels were below 2.5 mg/dl and 2 mg/dl, respectively, were included in this study. None of the patients received drugs altering phosphate metabolism and they did not change their routine diets. Urinary phosphate excretion and tubular phosphate reabsorption (TPR) were calculated before 3 weeks after dipyridamole treatment. Results:The mean levels of serum and urine (daily) phosphate and TPR were 1.68±0.36 mg/dl, 725.32±544.25 mg/day and 999.44±0.4, respectively. After treatment, the mean levels of serum-urine phosphate and TPR were 2.47±0.72 mg/dl, 667.91±259.85 mg/day and 999.69±0.22, respectively. Serum phosphate level and TPR were found to be significantly different before and after dipyridamole therapy. No significant change was observed in phosphate level before and after dipyridamole therapy. Conclusion:On Short-term dipyridamole treatment no negative effect was observed on renal functions in these cases. Although the number of cases included in this study is small, dipyridamole is an effective choice in management of hypophosphatemic RTRs.

Item Type: Article
Subjects: WA Public Health
Divisions: Journals > Medical J Mashhad University of Medical Sciences
Depositing User: mjmums mjmums
Date Deposited: 26 Nov 2017 17:48
Last Modified: 26 Nov 2017 17:48

Actions (login required)

View Item View Item